Trial Profile
A phase I study (investigator-initiated) on the safety and pharmacokinetics of Bortezomib with combination chemotherapy in pediatric and young adult patients with refractory acute lymphocytic leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Apr 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Hydrocortisone; Methotrexate; Prednisolone; Prednisolone; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms BZM-ALL-1
- 17 Dec 2015 Planned End Date changed from 31 Dec 2015 to 31 Mar 2016 as reported by University Hospital Medical Information Network - Japan record.
- 07 Apr 2015 Planned End Date changed from 30 Jun 2015 to 31 Dec 2015 as reported by University Hospital Medical Information Network - Japan record.
- 24 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan.